Results · Apr-Jun 2026
Sun Pharmaceutical Industries Q1 FY27 results
Sales grew 10% to ₹15,300 crore from ₹13,851 crore in Apr-Jun 2025.
Operating profit grew 3% to ₹4,418 crore, an operating margin of 28.9% (down 2.2 points from a year ago).
Net profit grew 27% to ₹2,901 crore from ₹2,293 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +5%, net profit +7%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 15,300 | 13,851 | +10% |
| Operating profit (EBITDA) | 4,418 | 4,302 | +3% |
| Operating margin | 28.9% | 31.1% | −2.2 pts |
| Net profit | 2,901 | 2,293 | +27% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.